Cel-Sci Corp (CVM) Stock Price, Quote & News

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 506 9460

Website: cel-sci.com

Address:

8229 Boone Boulevard, Suite 802, Vienna, United States

Cruiser24 Jul. 4 at 12:11 PM

$CVM BAULLIDK Dallah-pharma did not have a facility to manufacture MULTIKINE. Amorim does. Saudi is very very particular about the drugs given to its people. They are a people of high integrity. You can bet they ran Cel-sci over the coals while Dallas-pharma was pushing to get the BMD. “No lawsuits” is saying a mouth full after all these years. These two things alone just add to my bullish with attitude. And for the little micey clowns the audience the count down started over when Amarox took over. You must have your head stuck in the Bios. GOOD LUCK BULLS 💎💎💎💎💎. ✋🤚. 💎💎💎💎💎

0 · Reply

Cruiser24 Jul. 4 at 11:55 AM

$CVM BULLISK And the same goes to the rest of you that keep bad mouthing the greatest country on earth. Happy 250th to all that love America. LOVE IT OR LEAVE IT CLOSER GOOD. LUCK BULLS 💎💎💎💎💎 ✋🤚 💎💎💎💎💎

0 · Reply

frankinsense69 Jul. 4 at 3:20 AM

$DJT $CVM $NWBO The algae at the reflecting pool drew a bigger crowd than trump's state fair.

1 · Reply

topstockalerts Jul. 3 at 10:39 PM

$CVM this is actually holding up way better than I thought

2 · Reply

DeepThought Jul. 3 at 3:35 PM

$NWBO $CVM @frankinsense69 The realistic CAR‑T‑eligible population for NXC‑201 is not 38,500 patients. In the U.S., only about 800–1,000 patients per year meet the actual CAR‑T criteria. Globally, the real treatable population is roughly 1,500–2,000 patients per year. You should at least understand what you’re investing in, you clown!🤡

1 · Reply

frankinsense69 Jul. 3 at 3:03 PM

$CVM $NWBO Is @DeepThought ever right? https://immixbio.com/wp-content/uploads/2026/06/IMMX-Corporate-presentation-June-2026.pdf

1 · Reply

DeepThought Jul. 3 at 11:57 AM

$CVM @frankinsense69 IMMX’s global patient pool? Around 1,000 people spread across the planet, waiting for 100–300 annual slots. That’s not a market, that’s a boutique therapy! What’s Daddy doing now? Banging his dumb head against the wall and hoping intelligence magically appears? 🤡

0 · Reply

frankinsense69 Jul. 2 at 11:55 PM

$CVM john When plan b

0 · Reply

topstockalerts Jul. 2 at 10:22 PM

$CVM the market is giving this stock every chance to continue.

0 · Reply

BioGLovesMe Jul. 2 at 7:55 PM

$CVM Poor @MikeTechnician formerly @ichigodoranz aka one of @thebullrun s spam accounts desperately trying to get something to happen here. Geert loves each and every one of his loyal lemmings. Expect more dilution in the next 3-6 months to help fund the Stroopwafel Family Trust.

0 · Reply

CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026

Jun 24, 2026, 8:00 AM EDT - 10 days ago

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

Jun 16, 2026, 4:01 PM EDT - 18 days ago

CEL-SCI Announces Closing of Offering

2026-06-16T12:14:11.000Z - 18 days ago

CEL-SCI highlights dual-track strategy for Multikine

Jun 16, 2026, 8:00 AM EDT - 18 days ago

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

Jun 14, 2026, 7:03 PM EDT - 20 days ago

CEL-SCI Corporation Announces Pricing of Offering

2026-06-12T12:11:21.000Z - 22 days ago

CEL-SCI, Saudi Amarox to conduct signing ceremony for strategic agreement

Jun 12, 2026, 8:00 AM EDT - 22 days ago

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

2026-05-18T12:10:09.000Z - 6 weeks ago

CEL-SCI reports Q2 EPS (67c) vs. ($2.33) last year

May 18, 2026, 8:00 AM EDT - 6 weeks ago

CEL-SCI Reports Fiscal Second Quarter 2026 Results

May 13, 2026, 3:00 PM EDT - 7 weeks ago

CEL-SCI Announces Closing of Public Offering

2026-05-12T02:55:09.000Z - 7 weeks ago

CEL-SCI 6M share Secondary priced at $1.20

May 11, 2026, 8:11 PM EDT - 7 weeks ago

CEL-SCI Corporation Announces Pricing of Public Offering

2026-05-11T16:53:15.000Z - 7 weeks ago

CEL-SCI enters strategic agreement with Amarox over Multikine distribution

May 11, 2026, 8:00 AM EDT - 7 weeks ago

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

2026-04-17T21:13:20.000Z - 2 months ago

CEL-SCI files to sell 3.44M shares of common stock

Feb 18, 2026, 9:00 AM EST - 4 months ago

CEL-SCI Reports Fiscal First Quarter 2026 Results

Dec 29, 2025, 9:00 AM EST - 6 months ago

CEL-SCI Reports Fiscal 2025 Results

2025-11-07T21:35:28.000Z - 8 months ago

CEL-SCI files to sell 375,000 shares of common stock for holders

Oct 20, 2025, 9:00 AM EDT - 9 months ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 10, 2025, 8:00 AM EDT - 9 months ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Aug 29, 2025, 12:52 PM EDT - 11 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

2025-08-28T03:45:10.000Z - 11 months ago

CEL-SCI 1.11M share Spot Secondary priced at $9.00

Aug 27, 2025, 10:35 PM EDT - 11 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

2025-08-27T21:30:16.000Z - 11 months ago

CEL-SCI announces common stock offering, no amount given

Aug 27, 2025, 5:25 PM EDT - 11 months ago

CEL-SCI Announces Proposed Public Offering

2025-08-14T14:50:29.000Z - 11 months ago

CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year

Aug 14, 2025, 10:45 AM EDT - 11 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

2025-08-13T13:25:31.000Z - 11 months ago

CEL-SCI files for breakthrough designation for Multikine in Saudi Arabia

Aug 13, 2025, 9:15 AM EDT - 11 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Jul 14, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

2025-07-11T16:25:25.000Z - 1 year ago

CEL-SCI announces pricing of $5.7M at-the-market common stock offering

Jul 11, 2025, 12:16 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

2025-07-11T13:25:08.000Z - 1 year ago

CEL-SCI teams with Saudi Arabia pharmaceutical, healthcare company for Multikine

Jul 11, 2025, 9:15 AM EDT - 1 year ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jun 18, 2025, 9:00 AM EDT - 1 year ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

May 21, 2025, 8:14 PM EDT - 1 year ago

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 19, 2025, 2:40 PM EDT - 1 year ago

CEL-SCI Announces Combination of Common Stock

May 15, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

Apr 23, 2025, 8:30 AM EDT - 1 year ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 8, 2025, 9:51 AM EDT - 1 year ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Mar 24, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 18, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Feb 20, 2025, 8:00 AM EST - 1 year ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 18, 2025, 8:30 AM EST - 1 year ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Jan 14, 2025, 9:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Aug 15, 2024, 8:00 AM EDT - 2 years ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 2 years ago

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 2 years ago

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 8:23 AM EDT - 2 years ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Cruiser24 Jul. 4 at 12:11 PM

0 · Reply

Cruiser24 Jul. 4 at 11:55 AM

0 · Reply

frankinsense69 Jul. 4 at 3:20 AM

$DJT $CVM $NWBO The algae at the reflecting pool drew a bigger crowd than trump's state fair.

1 · Reply

topstockalerts Jul. 3 at 10:39 PM

$CVM this is actually holding up way better than I thought

2 · Reply

DeepThought Jul. 3 at 3:35 PM

1 · Reply

frankinsense69 Jul. 3 at 3:03 PM

$CVM $NWBO Is @DeepThought ever right? https://immixbio.com/wp-content/uploads/2026/06/IMMX-Corporate-presentation-June-2026.pdf

1 · Reply

DeepThought Jul. 3 at 11:57 AM

0 · Reply

frankinsense69 Jul. 2 at 11:55 PM

$CVM john When plan b

0 · Reply

topstockalerts Jul. 2 at 10:22 PM

$CVM the market is giving this stock every chance to continue.

0 · Reply

BioGLovesMe Jul. 2 at 7:55 PM

0 · Reply

MikeTechnician Jul. 2 at 7:17 PM

$CVM - express volume power hour, starting the impact

0 · Reply

Isitreallyhim Jul. 2 at 7:14 PM

$CVM Happy 4th to all my fellow patriots out there. 250 years of being the best country in the world. To all you whiney demmy "men" that hate our country and leader...... one way flights are cheap to Europe this year. CHEERS to all and maybe next week is the week. We'll see Lisa....we'll see

0 · Reply

MikeTechnician Jul. 2 at 6:50 PM

$CVM Loading zone loading time ? for the next leg, up!

0 · Reply

MikeTechnician Jul. 2 at 3:38 PM

$CVM - CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy https://finance.yahoo.com/healthcare/articles/cel-sci-advances-multikine-immunotherapy-120000636.html

1 · Reply

MikeTechnician Jul. 2 at 2:49 PM

$CVM Big day for a choice big potential, the bull incharge accumulation, green with trending into swing - that's is overview of yesterday making moves today.

0 · Reply

MikeTechnician Jul. 2 at 2:29 PM

$CVM bulls in charge volume support zone, loading

0 · Reply

BrandoS Jul. 2 at 2:25 PM

$CVM rip it boys

1 · Reply

JohnnySecretz Jul. 2 at 2:22 PM

$CVM without a catalyst the top is around $1.40

1 · Reply

TheRealBul Jul. 2 at 2:04 PM

$CVM The survival rate is highly underrated IMO. This could get shifty soon. Big boys want their money back and the Saudi's will pay for it.

1 · Reply

MikeTechnician Jul. 2 at 1:34 PM

$CVM Mover to watch - #CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies. https://youtu.be/MZQt_BY761M?si=I0gdDEqx0aFQtUac

0 · Reply

DeepThought Jul. 2 at 11:46 AM

$CVM

0 · Reply

BradBreath Jul. 2 at 11:41 AM

$CVM YO ✔️dont leave out NWBO Both are and have been LOOSERS BEEN YEARS NOTHING IS GOING TO HAPPEN , Time to think of cutting the losses Gambled and Lost 🫣

0 · Reply

Market Cap	19.92M
Revenue (ttm)	0.00
Net Income (ttm)	-25.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	658,500
Avg Vol	561,420
Day's Range	N/A - N/A
Shares Out	17.48M
Stochastic %K	86%
Beta	0.64
Analysts	Strong Sell
Price Target	$180.18